CDK19

CDK19

CDK19
Identifiers
AliasesCDK19, CDC2L6, CDK11, bA346C16.3, cyclin-dependent kinase 19, cyclin dependent kinase 19, DEE87, EIEE87
External IDsOMIM: 614720; MGI: 1925584; GeneCards: CDK19
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
2.7.11.22↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez

23097

78334

Ensembl

ENSG00000155111

ENSMUSG00000038481

UniProt

Q9BWU1

Q8BWD8

RefSeq (mRNA)

NM_001300960
NM_001300963
NM_001300964
NM_015076

NM_001168304
NM_001291816
NM_001291817
NM_198164

RefSeq (protein)

NP_001287889
NP_001287892
NP_001287893
NP_055891

NP_001161776
NP_001278745
NP_001278746
NP_937807

Location (UCSC)Chr 6: 110.61 – 110.82 MbChr 10: 40.22 – 40.36 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Cyclin-dependent kinase 19 is an enzyme that in humans is encoded by the CDK19 gene.[5][6][7]

Inhibitors

The natural product cortistatin A is a potent and selective inhibitor of CDK8 and CDK19.[8]

Romaciclib is a dual CDK8 and CDK19 inhibitor which is being developed for the treatment of acute myeloid leukaemia (AML).[9][10][11]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000155111 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000038481 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Serrao A, Jenkins LM, Chumanevich AA, Horst B, Liang J, Gatza ML, et al. (August 2018). "Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer". Oncogene. 37 (35): 4792–4808. doi:10.1038/s41388-018-0316-y. PMC 7018387. PMID 29780169.
  6. ^ Fant CB, Taatjes DJ (April 2019). "Regulatory functions of the Mediator kinases CDK8 and CDK19". Transcription. 10 (2): 76–90. doi:10.1080/21541264.2018.1556915. PMC 6602567. PMID 30585107.
  7. ^ Dannappel MV, Sooraj D, Loh JJ, Firestein R (2018). "Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules". Frontiers in Cell and Developmental Biology. 6 171. doi:10.3389/fcell.2018.00171. PMC 6340071. PMID 30693281.
  8. ^ Pelish HE, Liau BB, Nitulescu II, Tangpeerachaikul A, Poss ZC, Da Silva DH, et al. (Oct 2015). "Mediator kinase inhibition further activates super-enhancer-associated genes in AML". Nature. 526 (7572): 273–6. Bibcode:2015Natur.526..273P. doi:10.1038/nature14904. PMC 4641525. PMID 26416749.
  9. ^ "Romaciclib - Ryvu Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  10. ^ Rajendra A, Yee KW (April 2026). "Clinical development of a CDK8/19 kinase inhibitor for acute myeloid leukemia". Expert Opinion on Investigational Drugs. 35 (4): 253–256. doi:10.1080/13543784.2026.2656430. PMID 41931045.
  11. ^ Pakulska U, Obacz M, Woźnicki J, Wiklik K, Chakraborty S, Micek M, et al. (January 2026). "Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy". bioRxiv 10.64898/2025.12.16.693978.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.